Diabetes Poster - Does your child show any of these symptoms?
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden
Stop TB`s GDF provides a wide range of diagnostic equipment and laboratory supplies in its Diagnostics Catalog
World Drug Report 2017
-1-
Accessed: 14.03.2019
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
Die Initiative Medikamente gegen vernachlässigte Krankheiten (Drugs for Neglected Diseases initiative, DNDi) ist eine internationale gemeinnützige Organisation, die sichere, wirksame und bezahlbare Behandlungen für die am meisten vernachlässigten Patient:innen erforscht, entwickelt und bereitste...llt.
more
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada a las manos de las poblaciones más vulnerables ...del mundo.
more
L’initiative Médicaments contre les Maladies Négligées (DNDi) est une organisation internationale à but non lucratif spécialisée dans la recherche, le développement et la mise à disposition de traitements sûrs, efficaces et abordables aux patients les plus négligés.
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às mãos das populações mais vulneráveis do mund...o.
more
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Handbook of Foodborne Pathogenic Microorganisms and Natural Toxins
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and Local Representatives of regulated products to help in the continuous safety monitoring of products granted marketing authorization in Ghana.
Document No. : FDA/SMC/SMD/GL-RAR/2013/01
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition